--- title: "Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286613671.md" datetime: "2026-05-15T20:47:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286613671.md) - [en](https://longbridge.com/en/news/286613671.md) - [zh-HK](https://longbridge.com/zh-HK/news/286613671.md) --- # Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M Revenue: As of FY2026 Q2, the actual value is USD 1.667 M. EPS: As of FY2026 Q2, the actual value is USD -0.27. EBIT: As of FY2026 Q2, the actual value is USD -28.62 M. #### Overview Citius Oncology, Inc. reported $5.6 million in net revenue for the first half of fiscal 2026, with the LYMPHIR® launch progressing. The company secured up to $36.5 million in debt and equity capital. Broad payer coverage has been established with no reimbursement denials, and 83% of target accounts are either on formulary or under review . #### Revenue - Net Product Revenues for the three months ended March 31, 2026, were $1.7 million, compared to no revenue for the prior year period . - Net Product Revenues for the six months ended March 31, 2026, were $5.6 million, compared to no revenue for the prior year period . #### Gross Profit - Gross Profit for the three months ended March 31, 2026, was $1.3 million, representing an 80% margin . - Gross Profit for the six months ended March 31, 2026, was $4.5 million, representing an 80% margin . #### Operating Expenses - Research and Development (R&D) Expenses for the three months ended March 31, 2026, were $1.1 million, a decrease of $2.0 million from $3.1 million for the three months ended March 31, 2025 . - R&D Expenses for the six months ended March 31, 2026, were $2.1 million, a decrease of $2.3 million from $4.4 million for the six months ended March 31, 2025 . - General and Administrative (G&A) Expenses for the three months ended March 31, 2026, were $23.6 million, an increase of $21.4 million from $2.2 million for the three months ended March 31, 2025, primarily due to a $19.7 million one-time CMO contract cancellation charge . - G&A Expenses for the six months ended March 31, 2026, were $26.5 million, an increase of $21.9 million from $5.5 million for the six months ended March 31, 2025 . - Stock-based Compensation Expense for the three months ended March 31, 2026, was $3.5 million, compared to $2.1 million for the prior year period . - Stock-based Compensation Expense for the six months ended March 31, 2026, was $7.5 million, compared to $3.9 million for the prior year period . #### Other Income/Loss - A Gain on Sale of New Jersey Net Operating Losses of $1.76 million was reported . #### Net Loss - Net Loss for the three months ended March 31, 2026, was - $26.6 million, compared to a net loss of - $7.7 million for the three months ended March 31, 2025 . - Net Loss for the six months ended March 31, 2026, was - $32.1 million, compared to a net loss of - $14.4 million for the six months ended March 31, 2025 . #### Liquidity and Cash Flow - Cash and Cash Equivalents as of March 31, 2026, totaled $2.6 million . - Net Cash Used In Operating Activities for the six months ended March 31, 2026, was - $11.19 million . - Net Cash Used In Investing Activities for the six months ended March 31, 2026, was - $5.0 million, primarily due to license payments . - Net Cash Provided by Financing Activities for the six months ended March 31, 2026, was $14.89 million, mainly from net proceeds from the issuance of common stock . - Subsequent to quarter-end, the company secured up to $36.5 million in combined financing, including approximately $11.5 million in gross proceeds from warrant exercises and $10 million funded from a senior secured term loan facility, with up to an additional $15 million available subject to milestones . #### Operational Metrics - The LYMPHIR launch shows 83% of target accounts have added LYMPHIR or are actively progressing it through formulary review, with near 100% payer coverage for commercial lives and no reimbursement denials . - Inventory stood at $22.7 million of finished goods and work-in-process as of March 31, 2026, to support anticipated commercial demand . - Initial shipment of LYMPHIR to Europe has commenced as part of international distribution agreements across 19 markets . #### Outlook / Guidance Citius Oncology, Inc. expects its full commercial team to be deployed by mid-summer and possesses ample inventory for anticipated commercial demand . Following May 2026 financings, the company anticipates sufficient funds to operate through November 2026 . The company is also evaluating new bulk drug substance suppliers, with a letter of intent for a new contract manufacturing organization expected by the end of June 2026 . ### Related Stocks - [CTOR.US](https://longbridge.com/en/quote/CTOR.US.md) ## Related News & Research - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [REEVES CONFIRMS NO INCREASE IN UK FUEL DUTY IN 2026](https://longbridge.com/en/news/287213292.md)